Phico Therapeutics Ltd
Phico is a small biotechnology company developing a groundbreaking antibiotic platform technology known as SASPject. The technology is designed to target any harmful type of bacteria, including ‘superbugs’ such as MRSA and C. difficile. The technology utilises programmable delivery vectors to deliver genes encoding unique antibacterial proteins, SASP, to target bacteria. Phico’s first product, SASPject PT1.2 aimed at S. aureus, including MRSA, has completed a Phase I clinical trial. This product has shown rapid activity in culture against >200 clinical strains of S. aureus killing up to 99.9 % of MRSA bugs within two minutes.
Watch our member showcase video https://youtu.be/bJX22tD1Ymg